An international consortium of thousands of scientists is creating the Human Cell Atlas, a three-dimensional map of all the cells in the body. The goal is to understand all the cells that make up human tissues, organs and systems, which will enable multiple medical applications. This collection of cell maps is openly available for navigation at single-cell resolution, identified through omics analyses that reveal the tridimensional distribution of each cell. Read More

As a consequence of chronic liver disease progression, severe cirrhosis, decompensation and fibrosis culminates in end-stage liver disease (ESLD). There are no treatment options approved for ESLD, but, among others, regenerative therapies with autologous, nonengineered, pro-regenerative macrophages have shown good tolerability and improved transplant-free survival in the clinical setting. Read More

Voyager Therapeutics Inc. has selected a lead development candidate, VY-1706, for its tau silencing gene therapy program in Alzheimer’s disease. The company anticipates filing an IND application with the FDA and a clinical trial application (CTA) with Health Canada for VY-1706 in 2026. Read More

Aizen Therapeutics has emerged from stealth with a focus on early-stage programs powered by its novel drug discovery platform, Dax. Read More

The efficacy and capabilities of CVI Pharmaceuticals Inc.'s CVI-2742, a THR-β agonist, were tested in nonhuman primates. Read More

Interleukin-1 receptor-associated kinase 4 is critical in the modulation of inflammatory responses through Toll-like receptor and IL-1R signaling. Read More

Researchers from Ohio State University hypothesized that 12,13-diHOME may act by inhibiting the proarrhythmic molecule Ca2+/calmodulin-dependent kinase II (CaMKII). Read More

Sanofi SA has synthesized pyridoimidazolone compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors potentially useful for the treatment of cancer. Read More

The Wiskott-Aldrich syndrome protein (WASp) is expressed exclusively in hematopoietic cells and presents either an autoinhibited or activated conformation. EG-011 is a first-in-class activator of the autoinhibited form of WASp designed for the treatment of hematological cancers. Read More

Janssen Pharmaceutica NV has identified new compounds reported to be useful for the treatment of mycobacterial infections. Read More

Gruenenthal GmbH has patented new cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives acting as nociceptin receptor (OPRL1; KOR3; ORL1) agonists and thus reported to be useful for the treatment of pain. Read More

At the American Heart Association’s Scientific Sessions, E-Therapeutics plc presented preclinical data for ETX-258, a Galomic siRNA being developed for the treatment of heart failure. Read More

A patent from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. describes bicyclic heterocycle 5'-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer. Read More

Evotec International GmbH has disclosed integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease. Read More

Primary tumors arising in the gastrointestinal system, ovary or pancreas may spread and lead to secondary cancers such as metastatic omentum cancer. Read More